Amphastar Pharma (AMPH) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Join SI Premium – FREE
Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.92, $0.05 worse than the analyst estimate of $0.97. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $192.69 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xperi Corporation (XPER) Tops Q3 EPS by 3c; Offers Guidance
- e.l.f. Beauty, Inc. (ELF) Tops Q2 EPS by 64c, Beats on Revenue; Offers FY27 Guidance
- Corpay, Inc. (CPAY) Tops Q3 EPS by 35c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
